{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:16:35Z","timestamp":1793931395852,"version":"4.8.0"},"reference-count":47,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Department of Health Ma\u2019an Research Grant","award":["DOH\/ADHRTC\/2025\/360"],"award-info":[{"award-number":["DOH\/ADHRTC\/2025\/360"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2025,11,10]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We aimed to systematically review the real-world evidence (RWE) on the effectiveness and utilisation of advanced therapies for inflammatory bowel disease (IBD) in Middle Eastern populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>PubMed\/MEDLINE, Embase, Scopus, Web of Science and the Cochrane Central Register of Controlled Trials were searched up to May 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria<\/jats:title>\n                    <jats:p>Observational RWE studies investigating biologics or small molecules in Middle Eastern IBD patients (adult and paediatric) were included. Randomised controlled trials and case series with fewer than 10 patients were excluded. No language restrictions were applied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data extraction and synthesis<\/jats:title>\n                    <jats:p>Data were independently extracted by two reviewers. Due to significant heterogeneity in study design, populations and outcome reporting, a narrative synthesis was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 884 records, 23 studies were included, originating primarily from Saudi Arabia (n=8) and Iran (n=4). For anti-tumour necrosis factor (TNF) therapy, a Kuwaiti study of biologic-naive patients found 12-month endoscopic remission rates with infliximab of 56% for ulcerative colitis (UC) and 53% for Crohn\u2019s disease (CD), while a Saudi study reported higher odds of treatment failure with adalimumab versus infliximab (OR=26.91). Ustekinumab demonstrated strong efficacy, achieving 76.9% clinical remission at 52 weeks in a Saudi paediatric anti-TNF refractory IBD cohort and showing higher probability of effectiveness than vedolizumab in another Saudi study. In contrast, vedolizumab remission rates in advanced therapy-experienced UC patients were 89.3% with intensified dosing. Newer agents also showed promise; risankizumab induction led to 43.2% clinical remission in an Emirati CD cohort, while tofacitinib achieved clinical remission rates of 56.4% and 61.1% at 52 weeks in Lebanese and Iranian UC cohorts, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Advanced therapies for IBD appear to be effective in Middle Eastern cohorts; however, the available evidence is methodologically diverse, with substantial heterogeneity in study design, population characteristics and outcome reporting, which limits the ability to draw strong conclusions and highlights the need for further robust evaluation. Prospective, collaborative regional registries are imperative to address these gaps and inform local guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD420251083256.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgast-2025-002034","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T08:35:21Z","timestamp":1764664521000},"page":"e002034","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Utilisation and real-world effectiveness of advanced therapies for inflammatory bowel disease in Middle Eastern populations: a systematic review"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1673-7792","authenticated-orcid":false,"given":"Mohammed Nabil","family":"Quraishi","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Sheikh Shakhbout Medical City, Abu Dhabi, UAE"},{"name":"College of Medicine and Health Sciences, Khalifa University of Science and Technology, Abu Dhabi, UAE"},{"name":"Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam A","family":"Alahmad","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sheikh Shakhbout Medical City, Abu Dhabi, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ala I","family":"Sharara","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4009-8087","authenticated-orcid":false,"given":"Palak J","family":"Trivedi","sequence":"additional","affiliation":[{"name":"National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, Centre for Liver and Gastrointestinal Research and Gastrointestinal Research, National Institute of Health Research (NIHR) Birmingham Biomedical Research Centre (BRC), University of Birmingham, Birmingham, UK"},{"name":"Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK"},{"name":"Liver Unit, University Hospitals Birmingham Queen Elizabeth, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badr","family":"Al-Bawardy","sequence":"additional","affiliation":[{"name":"King Faisal Specialist Hospital and Research Centre, Riyadh, Riyadh Province, Saudi Arabia"},{"name":"Department of Internal Medicine, Section of Digestive Diseases, Yale School of Medicine, New Haven, CT, USA"},{"name":"College of Medicine, Alfaisal University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6340-8244","authenticated-orcid":false,"given":"Laith","family":"Alrubaiy","sequence":"additional","affiliation":[{"name":"Gastroenterology, St Mark\u2019s Hospital and Academic Institute, Harrow, West Glamorgan, UK"},{"name":"Swansea University Medical School, Swansea, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"2025120200351845000_12.1.e002034.1","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41586-025-08940-0","article-title":"Global evolution of inflammatory bowel disease across epidemiologic stages","volume":"642","author":"Hracs","year":"2025","journal-title":"Nature New Biol"},{"key":"2025120200351845000_12.1.e002034.2","first-page":"527","article-title":"Inflammatory bowel disease burden in the Middle East and North Africa Region: a comprehensive analysis of incidence, prevalence, and mortality from 1990-2019","volume":"37","author":"Alsakarneh","year":"2024","journal-title":"aog"},{"key":"2025120200351845000_12.1.e002034.3","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/jgh.15801","article-title":"Emerging inflammatory bowel disease demographics, phenotype, and treatment in South Asia, South\u2010East Asia, and Middle East: Preliminary findings from the Inflammatory Bowel Disease\u2010Emerging Nations\u2019 Consortium","volume":"37","author":"Banerjee","year":"2022","journal-title":"J of Gastro and Hepatol"},{"key":"2025120200351845000_12.1.e002034.4","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/ueg2.12317","article-title":"Implications of the changing epidemiology of inflammatory bowel disease in a changing world","volume":"10","author":"Agrawal","year":"2022","journal-title":"UEG Journal"},{"key":"2025120200351845000_12.1.e002034.5","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.cgh.2020.01.028","article-title":"Changing Global Epidemiology of Inflammatory Bowel Diseases: Sustaining Health Care Delivery Into the 21st Century","volume":"18","author":"Ananthakrishnan","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025120200351845000_12.1.e002034.6","doi-asserted-by":"crossref","unstructured":"Ahmed HA , Alzaabi MN , Swaid TK , et al . Evolving clinical burden of inflammatory bowel disease in the United Arab Emirates: a two-decade analysis of diagnoses and disease severity. Frontline Gastroenterol 2025;flgastro\u20132025. doi:10.1136\/flgastro-2025-103345","DOI":"10.1136\/flgastro-2025-103345"},{"key":"2025120200351845000_12.1.e002034.7","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(24)00983-8","article-title":"Inflammatory bowel disease has no borders: engaging patients as partners to deliver global, equitable and holistic health care","volume":"404","author":"Lamb","year":"2024","journal-title":"The Lancet"},{"key":"2025120200351845000_12.1.e002034.8","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S2468-1253(23)00193-0","article-title":"Representation and reporting of diverse groups in randomised controlled trials of pharmacological agents in inflammatory bowel disease: a systematic review","volume":"8","author":"Pathiyil","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025120200351845000_12.1.e002034.9","doi-asserted-by":"crossref","first-page":"146","DOI":"10.4103\/sjg.sjg_303_24","article-title":"A bibliometric analysis of inflammatory bowel disease research in the Arab world","volume":"31","author":"AlMuhaidib","year":"2025","journal-title":"Saudi J Gastroenterol"},{"key":"2025120200351845000_12.1.e002034.10","doi-asserted-by":"crossref","first-page":"6710","DOI":"10.3748\/wjg.v26.i43.6710","article-title":"First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus","volume":"26","author":"Alkhatry","year":"2020","journal-title":"WJG"},{"key":"2025120200351845000_12.1.e002034.11","first-page":"181","article-title":"Saudi consensus guidance for the management of inflammatory bowel disease during pregnancy","volume":"30","author":"Azzam","year":"2023","journal-title":"Saudi J Gastroenterol"},{"key":"2025120200351845000_12.1.e002034.12","first-page":"607","article-title":"Saudi consensus guidance for the diagnosis and management of inflammatory bowel disease in children and adolescents","volume":"45","author":"Saleem","year":"2024","journal-title":"Saudi Med J"},{"key":"2025120200351845000_12.1.e002034.13","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.4103\/sjg.sjg_277_22","article-title":"Saudi Arabia consensus guidance for the diagnosis and management of adults with inflammatory bowel disease","volume":"29","author":"Mosli","year":"2023","journal-title":"Saudi J Gastroenterol"},{"key":"2025120200351845000_12.1.e002034.14","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-1-2"},{"key":"2025120200351845000_12.1.e002034.15","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae190.1168","article-title":"P0994 Effectiveness of Risankizumab in an Emirati Crohn\u2019s Disease Cohort: Real-World Insights on Induction, Maintenance, and Dose Intensification Outcomes","volume":"19","author":"Alzaabi","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2025120200351845000_12.1.e002034.16","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae190.0977","article-title":"P0803 Biosimilar Therapy in IBD: Real-World Evidence from Saudi Arabia","volume":"19","author":"Mosli","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2025120200351845000_12.1.e002034.17","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.3390\/jcm11144157","article-title":"Predictors of Anti-TNF Therapy Failure among Inflammatory Bowel Disease (IBD) Patients in Saudi Arabia: A Single-Center Study","volume":"11","author":"Alharbi","year":"2022","journal-title":"JCM"},{"key":"2025120200351845000_12.1.e002034.18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.34172\/mejdd.2024.395","article-title":"Efficacy of Methotrexate and Anti-TNF Combination Therapy in Adults with Refractory Crohn\u2019s Disease","volume":"16","author":"Boustani","year":"2024","journal-title":"Middle East J Dig Dis"},{"key":"2025120200351845000_12.1.e002034.19","first-page":"S75","article-title":"Efficacy of infliximab and adalimumab therapy in very early onset, severe ulcerative colitis","volume":"14","author":"Rohani","year":"2021","journal-title":"Gastroenterol Hepatol Bed Bench"},{"key":"2025120200351845000_12.1.e002034.20","first-page":"6","article-title":"Promising effect of infliximab on the extent of involvement in ulcerative colitis","volume":"16","author":"Adibi","year":"2011","journal-title":"J Res Med Sci"},{"key":"2025120200351845000_12.1.e002034.21","unstructured":"Ahmed IS , Alwan AH , Alwan MH . Evaluation the response to infliximab therapy in patients with ulcerative colitis and crohn\u2019s disease. Syst Rev Pharm 2020. doi:10.31838\/srp.2020.12.173"},{"key":"2025120200351845000_12.1.e002034.22","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1388043","article-title":"Effectiveness of biologic therapies in achieving treatment targets in inflammatory bowel disease; real-world data from the Middle East (ENROLL study)","volume":"15","author":"Shehab","year":"2024","journal-title":"Front Pharmacol"},{"key":"2025120200351845000_12.1.e002034.23","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4103\/sjg.SJG_599_16","article-title":"Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis","volume":"23","author":"Hassan","year":"2017","journal-title":"Saudi J Gastroenterol"},{"key":"2025120200351845000_12.1.e002034.24","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4103\/sjg.sjg_434_22","article-title":"Exploring treatment of inflammatory bowel disease with infliximab in the Middle East and Northern Africa: An analysis of the HARIR observational cohort study","volume":"29","author":"Alharbi","year":"2023","journal-title":"Saudi J Gastroenterol"},{"key":"2025120200351845000_12.1.e002034.25","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.dld.2020.05.031","article-title":"Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in newly industrialised countries: The EXPLORE study","volume":"52","author":"Yamamoto-Furusho","year":"2020","journal-title":"Dig Liver Dis"},{"key":"2025120200351845000_12.1.e002034.26","doi-asserted-by":"crossref","first-page":"324","DOI":"10.4103\/sjg.sjg_101_24","article-title":"Short term effectiveness of ustekinumab versus vedolizumab in Crohn\u2019s disease after failure of anti-TNF agents: An observational comparative study design with a Bayesian analysis","volume":"30","author":"Alamer","year":"2024","journal-title":"Saudi J Gastroenterol"},{"key":"2025120200351845000_12.1.e002034.27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4103\/sjg.sjg_249_24","article-title":"The effectiveness of vedolizumab in advanced therapy-experienced ulcerative colitis patients: Real world data from the Inflammatory Bowel Disease of the Middle East (IBD-ME) Registry group","volume":"31","author":"Azzam","year":"2025","journal-title":"Saudi J Gastroenterol"},{"key":"2025120200351845000_12.1.e002034.28","doi-asserted-by":"crossref","unstructured":"Anbarserry D , Mosli M , Qari Y , et al . The use of therapeutic drug monitoring for early identification of vedolizumab response in Saudi Arabian patients with inflammatory bowel disease. Sci Rep 2023;13. doi:10.1038\/s41598-023-28566-4","DOI":"10.1038\/s41598-023-28566-4"},{"key":"2025120200351845000_12.1.e002034.29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4103\/sjg.sjg_7_24","article-title":"Clinical effectiveness and safety of ustekinumab in youth with refractory inflammatory bowel disease: A retrospective cohort study","volume":"31","author":"Alhadab","year":"2025","journal-title":"Saudi J Gastroenterol"},{"key":"2025120200351845000_12.1.e002034.30","first-page":"8","article-title":"The Long-Term Clinical Effectiveness of Ustekinumab in Antitumor Necrosis Factor-Experienced Crohn\u2019s Disease Patients","volume":"14","author":"Altuwaijri","year":"2022","journal-title":"Cureus"},{"key":"2025120200351845000_12.1.e002034.31","first-page":"S43","article-title":"Evaluating Upadacitinib in the Treatment of Moderate-To-Severe Active Inflammatory Bowel Disease, a Prospective Cohort, at a Tertiary Care Center in Riyadh, Saudi Arabia\u2019","volume":"30","author":"Almuaili","year":"2024","journal-title":"Saudi J Gastroenterol"},{"key":"2025120200351845000_12.1.e002034.32","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-024-03341-5","article-title":"Real world evidence on the effectiveness and safety of tofacitinib in ulcerative colitis in Lebanon","volume":"24","author":"Sharara","year":"2024","journal-title":"BMC Gastroenterol"},{"key":"2025120200351845000_12.1.e002034.33","doi-asserted-by":"crossref","first-page":"354","DOI":"10.34172\/aim.2021.52","article-title":"Efficacy and Safety of Tofacitinib for Treatment of Moderate to Severe Active Ulcerative Colitis: First Report from Iran","volume":"24","author":"Jameshorani","year":"2021","journal-title":"Arch Iran Med"},{"key":"2025120200351845000_12.1.e002034.34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4103\/sjg.sjg_336_21","article-title":"Early discontinuation of biological therapy among inflammatory bowel disease patients in Bahrain","volume":"28","author":"Abdulla","year":"2022","journal-title":"Saudi J Gastroenterol"},{"key":"2025120200351845000_12.1.e002034.35","doi-asserted-by":"crossref","DOI":"10.14309\/01.ajg.0000777084.18183.55","article-title":"S888\u2003Phenotype and Characteristics of Inflammatory Bowel Disease in the Gulf Region: Results From the First Prospective IBD Database in the United Arab Emirates","volume":"116","author":"Koutoubi","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"2025120200351845000_12.1.e002034.36","doi-asserted-by":"crossref","first-page":"i2232","DOI":"10.1093\/ecco-jcc\/jjae190.1408","article-title":"P1234 Inflammatory Bowel Disease Trends and Advanced Therapy Utilization: Insights from the UAE","volume":"19","author":"Ahmed","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2025120200351845000_12.1.e002034.37","doi-asserted-by":"crossref","first-page":"i2280","DOI":"10.1093\/ecco-jcc\/jjae190.1434","article-title":"P1260 Demographics and Clinical Characteristics of Inflammatory Bowel Disease in the Middle East and North Africa\u202f: A Multi-Nation Cross-sectional (MIRAGE) Study","volume":"19","author":"Shehab","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2025120200351845000_12.1.e002034.38","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000518003","article-title":"Incidence, Prevalence, and Clinical Epidemiology of Inflammatory Bowel Disease in the Arab World: A Systematic Review and Meta-Analysis","volume":"6","author":"Mosli","year":"2021","journal-title":"Inflamm Intest Dis"},{"key":"2025120200351845000_12.1.e002034.39","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12876-021-01745-1","article-title":"The emerging epidemic of inflammatory bowel disease in Asia and Iran by 2035: A modeling study","volume":"21","author":"Olfatifar","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"2025120200351845000_12.1.e002034.40","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae122","article-title":"The Groupe d\u2019Etude sur les Affections Inflammatoires Digestives (GETAID): 40 Years of a Family Story in Inflammatory Bowel Disease","volume":"19","author":"Laharie","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2025120200351845000_12.1.e002034.41","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/ajg.2016.236","article-title":"The Real-World Effectiveness and Safety of Vedolizumab for Moderate\u2013Severe Crohn\u2019s Disease: Results From the US VICTORY Consortium","volume":"111","author":"Dulai","year":"2016","journal-title":"American Journal of Gastroenterology"},{"key":"2025120200351845000_12.1.e002034.42","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/ecco-jcc\/jjad203","article-title":"Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource","volume":"18","author":"Kapizioni","year":"2024","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2025120200351845000_12.1.e002034.43","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S2468-1253(24)00044-X","article-title":"Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn\u2019s disease: 3-year data from the prospective, multicentre PANTS cohort study","volume":"9","author":"Chanchlani","year":"2024","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"2025120200351845000_12.1.e002034.44","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/ibd\/izae058","article-title":"Real-World Effectiveness of Ustekinumab in Ulcerative Colitis in a United States Multicenter Cohort Consortium","volume":"31","author":"Yarur","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2025120200351845000_12.1.e002034.45","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa145"},{"key":"2025120200351845000_12.1.e002034.46","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.gastrohep.2020.05.007","article-title":"El registro ENEIDA (Estudio Nacional en Enfermedad Inflamatoria intestinal sobre Determinantes gen\u00e9ticos y Ambientales) de GETECCU: dise\u00f1o, monitorizaci\u00f3n y funciones","volume":"43","author":"Zabana","year":"2020","journal-title":"Gastroenterolog\u00eda y Hepatolog\u00eda"},{"key":"2025120200351845000_12.1.e002034.47","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/ecco-jcc\/jjaa055","article-title":"Switching to a Second Thiopurine in Adult and Elderly Patients With Inflammatory Bowel Disease: A Nationwide Study From the ENEIDA Registry","volume":"14","author":"Calafat","year":"2020","journal-title":"J Crohns Colitis"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2025-002034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T08:35:27Z","timestamp":1764664527000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2025-002034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,1]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bmjgast-2025-002034"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2025-002034","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}